While Neuralink has been grabbing headlines due to its association with controversial billionaire Musk, other companies - ...

Vertex Pharma's non-opioid painkiller suzetrigine was unable to perform better than placebo in a phase 2 trial in lumbar ...

Novo Holdings' $16.5 billion acquisition of US contract development and manufacturing organisation (CDMO) Catalent has been ...

Novartis has said it will shut down two MorphoSys sites in Germany and the US, with the loss of around 330 jobs, after ...

First-degree murder charges are applied when there is suspicion of premeditated, intentional killing, while second-degree ...

China is the fourth major market where Kisunla has been approved after the US, Japan, and GB. It gets the green light there ...

The 2022 Inflation Reduction Act (IRA) has introduced significant challenges for the pharmaceutical industry, altering the ...

Anglo-US biotech Ottimo Pharma has completed a big early-stage biotech financing, raising $140 million for its PD-1 and VEGF ...

Specifically, that could include a ban on spread pricing – when a PBM reimburses pharmacies one price for a medicine, but ...

Dermatology specialist Galderma has claimed a second FDA approval for IL-31 inhibitor Nemluvio, adding atopic dermatitis to ...

An experimental therapy for Parkinson's disease being developed by Roche and Prothena has missed the mark in a phase 2b trial ...

The Series C – which was led by Novo Nordisk's parent company Novo Holdings – follows a $15 million second round for the ...